Definitive Radiation for High-Risk Spine Metastases

Sponsor: Stony Brook University

Sponsor score: 0
Inactive

ClinicalTrials ID:NCT06165419

Patient View

This clinical trial evaluates the efficacy of stereotactic body radiation therapy (SBRT) as a sole treatment for patients with aggressive spine metastases, potentially eliminating the need for extensive surgery. Eligible participants are those with high-risk spinal metastases. The intervention involves targeted SBRT to the affected spine areas, aiming to control tumor growth and alleviate symptoms.

Patient Parameters

Program Overview

This study is looking at whether patients with cancer that has aggressively spread to the spine can be treated with stereotactic body radiation therapy only and avoid a large spine surgery

Eligibility Criteria

Eligible patients must have:

  • Any pathologically proven solid tumor diagnosis not of central nervous system origin with radiographic or pathologic evidence of metastatic disease
  • Metastatic spine involvement documented by imaging
  • Involvement of maximum 3 contiguous vertebral bodies at the index site
  • Intact neurologic function, or only minor neurologic deficits with muscle strength greater or equal to 4 out of 5 with or without steroids
  • An evaluation by an radiation oncology and orthopedic spine/neurosurgery attending
  • ECOG Performance Status of 0-3

Patients are ineligible if they have:

  • An unstable spine defined as a Spinal Instability Neoplastic Score (SINS) greater than 12
  • Had previous surgery or radiation to address the target spinal metastases
  • Radiosensitive tumors (e.g. small cell lung cancer, lymphoma, multiple myeloma, and germ-cell tumors)

Get This Program In Your Inbox

You can sign up and apply your patients for this program.